PPL announces BSSL Phase II data

PPL (LSE:PTH) said that in a 6-patient trial, its transgenic Bile Salt Stimulated Lipase to treat pancreatic insufficiency was equivalent to a currently marketed product, Creon, at restoring fat absor...